Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006061|
Recruitment Status : Completed
First Posted : July 6, 2000
Last Update Posted : June 24, 2005
OBJECTIVES: I. Determine whether plasma choline and breast milk choline levels are low at fasting in a patient with methionine adenosyltransferase deficiency, and if the choline levels are low, determine whether choline levels respond to dietary supplementation with phosphatidylcholine.
II. Determine whether this patient has a fatty liver by magnetic resonance spectroscopy.
|Condition or disease||Intervention/treatment|
|Methionine Adenosyltransferase Deficiency Metabolism, Inborn Errors||Drug: phosphatidylcholine|
Blood is drawn for liver function tests and measurement of plasma choline levels and breast milk samples are taken for measurement of breast milk choline levels at fasting and at 1 hour after breakfast on day 1. The patient then undergoes magnetic resonance spectroscopy of the liver to assess liver density and choline compound mass. The patient then receives oral phosphatidylcholine supplement, and plasma and breast milk samples are taken at 3 and 6 hours after the dose. Oral phosphatidylcholine supplements continue for 30 days. The above studies are repeated on day 31.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1 participants|
|Study Start Date :||January 2000|
|Estimated Study Completion Date :||January 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006061
|Study Chair:||Steven H. Zeisel||UNC Lineberger Comprehensive Cancer Center|